Publications found:
254,506
Sort by:
ASIA-PACIFIC IBS-C DRUG MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDING The Asia-Pacific IBS-c drug market is predicted to grow at a CAGR of 6.29% over the forecast period of 2017-2025 and generate an estimated revenue of 210.28 ... habits and the pipeline drugs in the market are some of the major drivers for the Asian IBS-c drug market. The market is segmented according ...
July 2017
58 pages
ASIA-PACIFIC MARINE BIOTECHNOLOGY MARKET FORECAST 2017-2025
US$ 1,250.00
... The Asia-Pacific marine biotechnology market is expected to growth at a CAGR of 5.66% during the forecast period of 2016-2025. The revenue generated by the market is anticipated ... . A large scale exports of marine food products dominate the Asia Pacific Marine biotechnology market with China being the world’s ...
July 2017
62 pages
ASIA-PACIFIC MRI SYSTEMS MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDINGS The Asia Pacific MRI market is the fastest growing market. It was valued at $1351.48 million in 2016 and is expected to reach $2175 ... at a CAGR of 5.52% during the forecast period of 2017-2025. MARKET INSIGHTS India is the fastest growing market for MRI systems closely followed by Japan and South ...
July 2017
79 pages
ASIA-PACIFIC OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDINGS The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of ... and methyl naltrexone bromide and some pipeline drugs such as naldemedine, alvimopan, dolcanatide and ... branded prescribed drugs and over the counter drugs. A large number of considerations while using opioids is a ...
July 2017
54 pages
EUROPE IBS-C DRUG MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDINGS The Europe IBS-c drug market is expected to grow at a CAGR of 5.29% over the forecast period of 2017-2025. The market was valued at $468.6 million in the year 2016 ...
July 2017
54 pages
EUROPE MARINE BIOTECHNOLOGY MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDINGS The Europe marine biotechnology market is expected to grow at a CAGR of 5.28% during the forecast period of 2017-2025. The market value is expected to increase from $1210 million in the ...
July 2017
65 pages
EUROPE MRI SYSTEMS MARKET FORECAST 2017-2025
US$ 1,250.00
... The Europe MRI systems market was valued at $1579.84 million in 2016 and is expected to reach $2417.90 million by 2025 growing at a CAGR of 4.885% during the forecast period ...
July 2017
82 pages
EUROPE STEM CELL MARKET FORECAST 2017-2025
US$ 1,250.00
... Europe Stem cell market is estimated at $ 2010 million in the year 2016 and expected to reach $ 4540 million in the year 2025 at a CAGR of 9.38% during the forecast ... and the forecast period is between 2017 and 2025. The government’s subsidy and sustenance in the field of stem cell market, increasing investments ...
July 2017
85 pages
EUROPE OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDINGS The Europe opioid constipation drug market is expected to grow at a CAGR of 4.00% during the forecast period ... to $1273.34 million by 2025. MARKET INSIGHTS The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented ...
July 2017
52 pages
GLOBAL ANTI-DEPRESSANT DRUGS, DEVICES, AND THERAPIES MARKET FORECAST 2017-2025
US$ 2,500.00
KEY FINDINGS The Global Anti-depressant drugs, devices, and therapies market is anticipated to grow at a CAGR of 2.12% over the ... promise during the forecasted years. REGIONAL INSIGHTS Geographically, the global anti-depressant drugs, devices, and therapies market is segmented into: North America - U.S. & ...
July 2017
145 pages
GLOBAL IBS-C DRUG MARKET FORECAST 2017-2025
US$ 2,500.00
... Of these, the North America region is anticipated to dominate the global IBS-C drug market over the forecast period on account of its highly developed healthcare systems and ...
July 2017
112 pages
GLOBAL MARINE BIOTECHNOLOGY MARKET FORECAST 2017-2025
US$ 2,500.00
... FINDINGS The Global Marine Biotechnology market is expected to grow at a CAGR of 5.44% for the forecast period of 2017-2025. The market value is expected ... are majorly responsible for driving the global marine biotechnology market. MARKET INSIGHTS The Global marine biotechnology market is divided on the basis ...
July 2017
124 pages
GLOBAL OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025
US$ 2,500.00
... MARKET INSIGHTS The global Opioid Induced Constipation (OIC) drug market segments include drug type and prescription type. Drug types are further ... strategy adopted by the various market players of global Opioid Induced Constipation (OIC) drug market.The AstraZeneca Pharmaceuticals’s Movantik developed a ...
July 2017
113 pages
GLOBAL STEM CELL MARKET FORECAST 2017-2025
US$ 2,500.00
KEY FINDINGS The global market for stem cell is anticipated to expand at a CAGR of 9.68% during the forecast period of 2017-2025. The ... rise in neurodegenerative diseases is the primary factor for the growth of the stem cell market. MARKET INSIGHTS The global stem cell market ...
July 2017
132 pages
NORTH AMERICA IBS-C DRUG MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FACTORS The North American IBS-c drug market was valued at $439.5 million in 2016. The market is expected to grow at a CAGR of 7.30% and generate $825.07 million by 2025. The ...
July 2017
55 pages
NORTH AMERICA MARINE BIOTECHNOLOGY MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDINGS The North America marine biotechnology market is anticipated to grow at a CAGR of 5.39% over the forecast period of 2017-2025. Likewise, the revenue generated by the market is touted to increase ...
July 2017
72 pages
NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDINGS The North America opioid induced constipation drug market is expected to be the fastest growing market during the ... in 2016 and reach $1382.73 million by 2025. MARKET INSIGHTS The North American OIC drug market is segmented on the basis of the type ...
July 2017
51 pages
Adherence – What Do Pharma Really Know
US$ 695.00
Adherence – What Do Pharma Really Know The entire industry is talking about patient centricity ... as they are intended to be taken and reap the benefits accordingly? Adherence: What do pharma really know? explores the main issues including physician impact ...
July 2017
AML [2017]: Bulletin #2
US$ 1,045.00
This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics ... to recommend the approval of Pfizer’s Mylotarg in previously untreated, de novo AML patients? To what extent is the ALFA-0701 trial considered compelling ...
July 2017
Bladder Cancer [2017]
US$ 8,145.00
... to differentiate their marketed and pipeline therapies in KOL Insight: Bladder Cancer. Twelve US and European KOLs provide their candid insights on ... how do KOLs view Cyramza (ramucirumab) as a potential treatment for bladder cancer? What will be critical for commercial success in this indication? Which ...
July 2017
Breast Cancer [2017]: Bulletin #1
US$ 1,045.00
... events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from ...
July 2017
CLL [2017]
US$ 8,145.00
... to differentiate their pipeline therapies in KOL Insight: Chronic Lymphocytic Leukaemia (CLL). Twelve US and European KOLs provide their candid insights on seven ... oral targeted drugs? How will Imbruvica’s role evolve in treatment of CLL? Following expanded approval of Janssen/AbbVie’s Imbruvica to first-line ...
July 2017
Cystic Fibrosis [2017]: Bulletin #2
US$ 1,045.00
This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; ... ) which were presented at the 40th European Cystic Fibrosis Society Conference in Seville, Spain in June 2017; and Verona Pharma initiating a Phase II ...
July 2017
HNSCC [2017]: Bulletin #2
US$ 1,045.00
... with solid tumours, including HNSCC, were presented at ASCO 2017; Merck & Co. announced ... that the Phase III KEYNOTE-040 trial of Keytruda in previously treated patients with recurrent or metastatic HNSCC ... potential combination treatment regimens for HNSCC? How do KOLs interpret the ...
July 2017
Market Access Impact (EU5) [NSCLC]
US$ 5,145.00
... narrow, but significant lead. Get the details in Market Access Impact: NSCLC (EU5). You’ll see how widely prescribed your brand is, ... Pfizer/Merck Group) Zykadia (ceritinib; Novartis) Exploring Market Access Barriers Market Access Impact: NSCLC (EU5) explores key issues affecting drug manufacturers. You’ll ...
July 2017
Market Access Impact (US) [NSCLC]
US$ 5,145.00
... to overtake their closest rivals. Get the details in Market Access Impact: NSCLC (US). You’ll see how widely prescribed your brand is, ... Pfizer/Merck Group) Zykadia (ceritinib; Novartis) Exploring Market Access Barriers Market Access Impact: NSCLC (US) explores key issues affecting drug manufacturers. You’ll ...
July 2017
Medical Affairs Reputations (EU5) [CLL]
US$ 6,175.00
... more of; and why some are dissatisfied. Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (EU5) to discover how your team can better meet ... What specifically are they asking for? Insight into Medical Affairs Teams for These CLL Brands Arzerra (ofatumumab; Novartis/Genmab) Gazyvaro (obinutuzumab ...
July 2017
Medical Affairs Reputations (EU5) [Growth Hormone Deficiency]
US$ 6,175.00
... down Our latest survey shows that while medical affairs teams for growth hormone brands in the EU5 countries (France, Germany, Italy, Spain, ... doctors, and get a leg up on the competition, in Medical Affairs Reputations: GHD (EU5). Comparing 7 major growth hormone brands from Eli Lilly, Ipsen, Ferring, Merck ...
July 2017
Medical Affairs Reputations (US) [CLL]
US$ 6,175.00
... want to see more of; and why some are dissatisfied. Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (US) to discover how your team can ... Could addressing these tip the balance? Insight into Medical Affairs Teams for These CLL Brands Arzerra (ofatumumab; Novartis) Gazyva (obinutuzumab; Roche ...
July 2017
Medical Affairs Reputations (US) [Growth Hormone Deficiency]
US$ 6,175.00
... doctors down Our latest survey shows that while medical affairs teams for growth hormone brands in the EU5 countries (France, Germany, Italy ... with doctors, and get a leg up on the competition, in Medical Affairs Reputations: GHD (EU5). Comparing 7 major growth hormone brands from Eli Lilly, Ipsen, Ferring ...
July 2017
Melanoma [2016]: Bulletin #3
US$ 1,045.00
... the arrival of Array BioPharma’s binimetinib/encorafenib combination to the melanoma treatment landscape? How does Array’s binimetinib/encorafenib compare to Novartis ... give way to Imlygic/Keytruda? What do KOLs think? Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement ...
July 2017
Multiple Sclerosis [2016]: Bulletin #3
US$ 1,045.00
... ) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche reporting that a German ... of Mavenclad (cladribine) for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity, and presenting new ...
July 2017
NASH [2017]: Bulletin #1
US$ 1,045.00
... shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the ... of acetyl-CoA carboxylase (ACC), in patients with NASH. Business Questions: How do KOLs view the positive ... GS-0976 at EASL 2017, and are they hopeful about the therapy in NASH? Are the experts ...
July 2017
NPS+ (EU5) [Haemophilia A]
US$ 2,575.00
... for improvement. Find out what they are in FirstView’s NPS+ Haemophilia A 2017 (EU5). You’ll learn how doctors rated your brand, get insight ... and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia A 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers ...
July 2017
NPS+ (EU5) [Haemophilia B]
US$ 2,575.00
... score in FirstView’s NPS+ Haemophilia B 2017 (EU5). Building on the respected net promoter score (NPS), the report compares six major haemophilia drugs, and shows ... and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia B 2017 (EU5) explores key issues affecting brand loyalty for drug ...
July 2017
NPS+ (EU5) [RA]
US$ 2,575.00
... Spain, Germany, Italy and the UK. NPS+ Rheumatoid Arthritis (EU5) provides clear insight into the results, giving ... . Explore Important Brand Loyalty Issues NPS+ Rheumatoid Arthritis (EU5) gives you clear and independent ... the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into ...
July 2017
NPS+ (US) [Haemophilia A]
US$ 2,575.00
... satisfaction score in FirstView’s NPS+ Haemophilia A 2017 (US). Building on the respected net promoter score (NPS), the report compares nine major haemophilia A drugs, and ... 1st and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia A 2017 (US) explores key issues affecting brand loyalty for ...
July 2017
NPS+ (US) [Haemophilia B]
US$ 2,575.00
... score in FirstView’s NPS+ Haemophilia B 2017 (US). Building on the respected net promoter score (NPS), the report compares six major haemophilia drugs, and shows ... 1st and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia B 2017 (US) explores key issues affecting brand loyalty for ...
July 2017
NPS+ (US) [RA]
US$ 2,575.00
... You Need to Grow. How does NPS work? NPS measures overall brand satisfaction and loyalty ... , 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5. NPS can range from -100 (everybody is a Detractor) to + ... the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into ...
July 2017
NSCLC [2017]
US$ 8,145.00
How will immunotherapy combination regimens impact the NSCLC treatment landscape? The pace of change in NSCLC shows no sign of abating. Developments in immunotherapy ... approvals, could shake up the treatment algorithm for ALK-positive NSCLC, as well as developments in EGFR-, BRAF- and ROS1-positive disease ...
July 2017
Payer attitudes to Orphan Drug pricing
US$ 2,245.00
Payer Attitudes to Orphan Drug Funding The explosion of orphan drugs across Europe and the US is pushing healthcare finances towards breaking point according to payers. Requests for orphan drug designation have reached ...
July 2017
Payer Insights: RA [2016]: Bulletin #3
US$ 1,045.00
... to alter the RA treatment algorithm? What level of discount do payers demand in order to facilitate market penetration of biosimilar adalimumab? How ... RA? What factors will drive the acceptance of biosimilars by payers? How will payers manage the use of biosimilars in treatment-naïve and treatment-experienced ...
July 2017
Global Pharmaceutical Equipment Testing Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
US$ 4,200.00
... global pharmaceutical packaging testing equipment market is segmented into container testing, container closure integrity testing, life testing, visual inspection and functional testing, stability testing, raw material testing, method validation, microbial testing ...
July 2017
350 pages
Bio Pharma Market in India 2017
US$ 950.00
... order is placed. Netscribes' latest market research report titled Bio Pharma Market in India 2017 states that while historically the ... market. COVERAGE: Overview of the bio pharma market in India, and historical and forecasted market size data over 2010 to 2022 Trade analysis of bio pharma products in India ...
July 2017
53 pages
2017 Global and Regional Aesthetic Lasers and Energy Devices Market Research Report Forecasts 2022
US$ 2,800.00
This report focus on Global and regional market, providing information on major players like manufacturers, suppliers, distributors, ... etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia (Excluding China ...
July 2017
140 pages
2017 Global and Regional Medical Pressure Transducers Market Research Report Forecasts 2022
US$ 2,800.00
... etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia ... follows: Edwards Lifesciences, Smiths Medical, Argon, ICU Medical, Merit Medical Systems, Biosenor International, ANTMED, Utah Medical, JUNKEN MEDICAL, Ace Medical, Major types are as ...
July 2017
167 pages
2017 Global and Regional Orthopedic Devices Market Research Report Forecasts 2022
US$ 2,800.00
This report focus on Global and regional market, providing information on major players like manufacturers, suppliers, distributors, ... etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia (Excluding China ...
July 2017
146 pages
